Trial Profile
Phase I trial of MA09-retinal-pigment-epithelial-cell-replacement-therapy-Advanced-Cell-Technology (RPE cells) in Asian patients with Stargardt's macular degeneration and dry age-related macular degeneration
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Jul 2017
Price :
$35
*
At a glance
- Drugs MA09 retinal pigment epithelial cell replacement therapy-Astellas Pharma (Primary)
- Indications Dry age-related macular degeneration; Stargardt disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Ocata Therapeutics
- 10 Aug 2015 New trial record
- 06 Aug 2015 Positive top-line results reported, according to an Ocata Therapeutics media release.